Health Care & Life Sciences » Biotechnology | Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Inc. | Ownership

Companies that own Progenics Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
BlackRock Fund Advisors
10,789,415
12.87%
1,294,965
0%
06/30/2018
Federated Global Investment Management Corp.
6,996,055
8.34%
-3,191,708
0.39%
06/30/2018
Eagle Asset Management, Inc.
4,461,482
5.32%
-9,356
0.16%
06/30/2018
SSgA Funds Management, Inc.
4,168,524
4.97%
416,190
0%
06/30/2018
The Vanguard Group, Inc.
4,166,898
4.97%
263,031
0%
06/30/2018
Carillon Tower Advisers, Inc.
3,948,024
4.71%
0
0.23%
06/30/2018
Farallon Capital Management LLC
2,651,100
3.16%
2,651,100
0.14%
06/30/2018
Armistice Capital LLC
2,536,000
3.02%
136,000
1.51%
06/30/2018
Ardsley Advisory Partners
2,130,000
2.54%
0
2.59%
06/30/2018
Pinnacle Associates Ltd.
1,789,073
2.13%
-312,595
0.27%
06/30/2018

About Progenics Pharmaceuticals

View Profile
Address
One World Trade Center
New York New York 1000
United States
Employees -
Website http://www.progenics.com
Updated 07/08/2019
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.